article thumbnail

One Person’s Journey from Celebrity Medical Model Advocate to Skeptic: An Interview with Rose Cartwright

Mad in America

You write that you worry about how psychedelics are getting co-opted by pharmaceutical industries. Cartwright: I do an exercise in my book where I speculate that if psychedelic therapy been available to my mother when she was at her worst, would it have been helpful? Tell us more. Please speak about that.

article thumbnail

A Win for Science, with Profound Implications for Industry: FDA Rejects MDMA

Mad in America

L ykos Therapeutics experienced a double blow this week, with the FDA’s rejection of their proprietary MDMA-assisted therapy for PTSD and the retraction of three articles on MDMA’s supposed efficacy.

article thumbnail

Set, Setting, Forgetting: Silence on Abuse in Psychedelic Therapy Histories

Mad in America

Psychedelic therapy advocates consistently dismiss these concerns as exaggerated or isolated incidents that are inevitable in any therapy. The book draws from Passies earlier academic work, including his 2018 journal article “The Early Use of MDMA (Ecstasy) in Psychotherapy (19771985).”